Genmab A/S (NASDAQ:GMAB) Shares Bought by Bleakley Financial Group LLC

Bleakley Financial Group LLC lifted its position in shares of Genmab A/S (NASDAQ:GMAB) by 7.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,732 shares of the company’s stock after buying an additional 2,196 shares during the period. Bleakley Financial Group LLC’s holdings in Genmab A/S were worth $749,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. grew its position in Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares during the period. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after purchasing an additional 749 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of Genmab A/S during the 1st quarter worth about $43,000. Headlands Technologies LLC raised its holdings in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after buying an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. lifted its position in Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Down 0.9 %

Genmab A/S stock opened at $22.78 on Tuesday. The firm has a market capitalization of $15.06 billion, a P/E ratio of 18.98, a P/E/G ratio of 0.71 and a beta of 0.98. Genmab A/S has a twelve month low of $22.52 and a twelve month high of $32.89. The stock’s fifty day simple moving average is $25.66 and its 200-day simple moving average is $27.01.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. Sell-side analysts predict that Genmab A/S will post 1.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GMAB. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. BTIG Research boosted their target price on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.